- Home
- MDGL
as 11-12-2025 3:42pm EST
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 9.6B | IPO Year: | N/A |
| Target Price: | $523.92 | AVG Volume (30 days): | 409.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $265.00 - $544.25 | Next Earning Date: | 11-04-2025 |
| Revenue: | $740,640,000 | Revenue Growth: | 864.21% |
| Revenue Growth (this year): | 395.75% | Revenue Growth (next year): | 65.73% |
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BATE KENNETH | MDGL | Director | Nov 5 '25 | Sell | $485.61 | 16,575 | $8,027,354.15 | 14,180 | |
| Sibold William John | MDGL | President and CEO | Sep 9 '25 | Sell | $445.63 | 7,279 | $3,243,740.77 | 102,474 | |
| Sibold William John | MDGL | President and CEO | Aug 21 '25 | Sell | $400.52 | 7,616 | $3,047,756.37 | 102,474 | |
| BAKER BROS. ADVISORS LP | MDGL | N/A | Aug 20 '25 | Buy | $384.95 | 59,901 | $23,071,366.47 | 201,720 | |
| BAKER BROS. ADVISORS LP | MDGL | N/A | Aug 18 '25 | Buy | $364.61 | 105,782 | $38,849,657.82 | 201,720 | |
| Kelley Shannon T | MDGL | General Counsel | Aug 18 '25 | Sell | $371.08 | 1,304 | $479,626.86 | 9,173 | |
| BATE KENNETH | MDGL | N/A | Aug 15 '25 | Sell | $365.88 | 10,000 | $3,652,008.56 | 14,180 |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
Zacks
a month ago
Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?
GlobeNewswire
a month ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
3 months ago
Madrigal Pharmaceuticals Insider Sold Shares Worth $3,047,756, According to a Recent SEC Filing
GlobeNewswire
3 months ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
3 months ago
Madrigal Pharmaceuticals Wins EU Approval for Rezdiffra
GlobeNewswire
3 months ago
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Insider Monkey
5 months ago
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
Pharmaceutical Technology
5 months ago
Madrigal poised to enter European MASH market after CHMP endorsement
Compare MDGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.